BioAtla (BCAB) News Today $0.30 -0.04 (-11.79%) Closing price 04:00 PM EasternExtended Trading$0.29 -0.01 (-2.30%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period HC Wainwright Reaffirms Neutral Rating for BioAtla (NASDAQ:BCAB)April 2 at 1:27 AM | americanbankingnews.comH.C. Wainwright Keeps Their Hold Rating on BioAtla (BCAB)March 31 at 6:23 PM | markets.businessinsider.comBioAtla price target lowered to $1 from $5 at Citizens JMPMarch 31 at 6:23 PM | markets.businessinsider.comBioAtla, Inc. (NASDAQ:BCAB) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comEarnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock risesMarch 29, 2025 | uk.investing.comBioAtla price target lowered to $10 from $13 at BTIGMarch 29, 2025 | markets.businessinsider.comBioAtla announces restructuring, to cut over 30% of workforceMarch 28, 2025 | markets.businessinsider.comBioAtla, Inc. (BCAB) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comBioAtla Cuts 30% of Jobs in Restructuring EffortMarch 27, 2025 | marketwatch.comBioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent ProgressMarch 27, 2025 | globenewswire.comEarnings Outlook For BioAtlaMarch 27, 2025 | benzinga.comBioAtla Announces Two Poster Presentations at Upcoming Medical MeetingsMarch 20, 2025 | globenewswire.comBioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025March 19, 2025 | globenewswire.comAXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)March 4, 2025 | globenewswire.comBioAtla faces Nasdaq delisting over share price ruleFebruary 8, 2025 | msn.comBioAtla Secures $9.2M for Clinical Program AdvancementsDecember 21, 2024 | markets.businessinsider.comBioAtla Highlights Advancements in CAB Cancer TherapyDecember 20, 2024 | markets.businessinsider.comBioAtla to sell 9.68M shares at 95.2c in registered direct offeringDecember 20, 2024 | markets.businessinsider.comBioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection PointsDecember 20, 2024 | globenewswire.comBioAtla presents data on mecbotamab vedotin in advanced NSCLCDecember 17, 2024 | markets.businessinsider.comBioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science MeetingDecember 16, 2024 | globenewswire.comBioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science MeetingDecember 10, 2024 | globenewswire.comGSA Capital Partners LLP Purchases New Position in BioAtla, Inc. (NASDAQ:BCAB)GSA Capital Partners LLP acquired a new stake in BioAtla, Inc. (NASDAQ:BCAB - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 353,769 shares of the company's stock, valued at approximately $623,000. GSANovember 19, 2024 | marketbeat.comBioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 7.1% in OctoberBioAtla, Inc. (NASDAQ:BCAB - Get Free Report) was the target of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 4,870,000 shares, a decrease of 7.1% from the October 15th total of 5,240,000 shares. Based on an average trading volume of 1,210,000 shares, the short-interest ratio is currently 4.0 days.November 18, 2024 | marketbeat.comFY2024 Earnings Forecast for BioAtla Issued By HC WainwrightBioAtla, Inc. (NASDAQ:BCAB - Free Report) - Investment analysts at HC Wainwright issued their FY2024 earnings estimates for BioAtla in a research report issued on Wednesday, November 13th. HC Wainwright analyst A. He expects that the company will post earnings per share of ($1.46) for the year. HNovember 15, 2024 | marketbeat.comMichael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 tradesNovember 14, 2024 | msn.comBioAtla: Strong Financials and Promising Clinical Progress Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comHC Wainwright & Co. Downgrades BioAtla (BCAB)November 14, 2024 | msn.comBioAtla (BCAB) was downgraded to a Hold Rating at H.C. WainwrightNovember 14, 2024 | markets.businessinsider.comHC Wainwright Downgrades BioAtla (NASDAQ:BCAB) to NeutralHC Wainwright lowered shares of BioAtla from a "buy" rating to a "neutral" rating in a research report on Wednesday.November 13, 2024 | marketbeat.comBioAtla, Inc. (NASDAQ:BCAB) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | msn.comBioAtla Reports Q3 2024 Financial Results and Clinical AdvancesNovember 9, 2024 | markets.businessinsider.comBioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesNovember 9, 2024 | finance.yahoo.comBioAtla, Inc. (BCAB) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comBioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent ProgressNovember 7, 2024 | markets.businessinsider.comBioAtla (BCAB) to Release Quarterly Earnings on ThursdayBioAtla (NASDAQ:BCAB) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comBioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stakeOctober 31, 2024 | finance.yahoo.comBioAtla, Inc. (NASDAQ:BCAB) Sees Large Increase in Short InterestBioAtla, Inc. (NASDAQ:BCAB - Get Free Report) was the target of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 5,240,000 shares, a growth of 17.2% from the September 30th total of 4,470,000 shares. Based on an average daily volume of 1,180,000 shares, the short-interest ratio is currently 4.4 days.October 28, 2024 | marketbeat.comBioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025October 20, 2024 | msn.com636,136 Shares in BioAtla, Inc. (NASDAQ:BCAB) Acquired by AQR Capital Management LLCAQR Capital Management LLC acquired a new stake in BioAtla, Inc. (NASDAQ:BCAB - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 636,136 shares of the company's stock, valued at approximatelOctober 13, 2024 | marketbeat.comBioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial ChallengesOctober 10, 2024 | finance.yahoo.comBioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative BuyOctober 8, 2024 | seekingalpha.comRenaissance Technologies LLC Decreases Stock Holdings in BioAtla, Inc. (NASDAQ:BCAB)Renaissance Technologies LLC trimmed its holdings in shares of BioAtla, Inc. (NASDAQ:BCAB - Free Report) by 37.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 625,500 shares of the company's stock after selling 370,800 shOctober 8, 2024 | marketbeat.comBioAtla: Numerous Catalysts Coming In Q4October 7, 2024 | seekingalpha.comBioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual MeetingOctober 4, 2024 | globenewswire.comBioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International CongressOctober 1, 2024 | markets.businessinsider.comBioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International CongressOctober 1, 2024 | globenewswire.comMichael Burry just bought 633,959 shares in this $1 penny stockSeptember 30, 2024 | msn.comScion Asset Management LLC Purchases Shares of 633,959 BioAtla, Inc. (NASDAQ:BCAB)Scion Asset Management LLC purchased a new stake in BioAtla, Inc. (NASDAQ:BCAB - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 633,959 shares of the company's stock, valued at approximately $869,00September 27, 2024 | marketbeat.comBuy Rating Affirmed for BioAtla Amidst Strategic Collaborations and Promising Clinical CatalystsSeptember 24, 2024 | markets.businessinsider.com Remove Ads Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address BCAB Media Mentions By Week BCAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCAB News Sentiment▼0.290.60▲Average Medical News Sentiment BCAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCAB Articles This Week▼141▲BCAB Articles Average Week Remove Ads Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CTOR News ABOS News PYRGF News CRBP News ASRT News JSPR News THTX News ZIVO News INCR News ACRV News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCAB) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCAB Stock Free BCAB Stock Alerts